Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $34.58 USD
Change Today -0.30 / -0.86%
Volume 164.1K
BRLI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for bio-reference labs inc (BRLI)

This company's debt to total capital ratio, at 14.81%, is in-line with the Healthcare Providers and Services industry's norm. Additionally, an examination of near-term assets and liabilities shows that there are enough liquid assets to satisfy current obligations.. Cash Collection is a strong suit as the company is more effective than most in the industry. As of the end of 2014, its uncollected receivables totaled $263.3M USD, which, at the current sales rate provides a Days Receivables Outstanding of 102.97. Last, inventories seem to be well managed as the Inventory Processing Period is typical for the industry, at 16.44 days.
Currency in
Millions of US Dollars
As of:Oct 31
2011
Reclassified
Oct 31
2012
Reclassified
Oct 31
2013
Oct 31
2014
4 Year
Trend
Assets    
Cash and Equivalents22.025.118.017.5
TOTAL CASH AND SHORT TERM INVESTMENTS22.025.118.017.5
Accounts Receivable148.1153.2206.3263.3
TOTAL RECEIVABLES148.1153.2206.3263.3
Inventory9.714.919.120.8
Deferred Tax Assets, Current22.624.942.240.0
Other Current Assets4.55.49.410.2
TOTAL CURRENT ASSETS206.8223.6294.9351.8
Gross Property Plant and Equipment81.7102.7133.6156.3
Accumulated Depreciation-38.1-52.3-67.9-90.0
NET PROPERTY PLANT AND EQUIPMENT43.650.465.666.4
Goodwill23.423.435.235.2
Long-Term Investments--5.05.25.2
Deferred Tax Assets, Long Term1.02.32.13.4
Other Intangibles6.96.316.314.4
Other Long-Term Assets1.61.82.22.5
TOTAL ASSETS283.3312.8421.5478.9
    
LIABILITIES & EQUITY    
Accounts Payable38.641.361.671.2
Accrued Expenses11.816.519.615.8
Short-Term Borrowings18.6--26.133.4
Current Portion of Long-Term Debt/Capital Lease4.34.45.76.7
Current Portion of Capital Lease Obligations3.04.05.26.1
Current Income Taxes Payable8.99.818.315.6
Other Current Liabilities, Total0.4--2.41.9
TOTAL CURRENT LIABILITIES82.572.0133.8144.6
Long-Term Debt4.64.23.73.1
Capital Leases6.49.510.712.3
Other Non-Current Liabilities----1.8--
TOTAL LIABILITIES93.585.6149.9160.0
Common Stock0.30.30.30.3
Additional Paid in Capital45.640.939.440.0
Retained Earnings143.9186.1231.9278.6
TOTAL COMMON EQUITY189.8227.2271.6318.9
TOTAL EQUITY189.8227.2271.6318.9
TOTAL LIABILITIES AND EQUITY283.3312.8421.5478.9
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BRLI:US $34.58 USD -0.30

BRLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $2.70 USD +0.04
Genomic Health Inc $30.38 USD -0.84
Myriad Genetics Inc $35.34 USD -0.155
NeoGenomics Inc $4.84 USD +0.02
Sequenom Inc $4.28 USD -0.06
View Industry Companies
 

Industry Analysis

BRLI

Industry Average

Valuation BRLI Industry Range
Price/Earnings 19.1x
Price/Sales 1.1x
Price/Book 2.9x
Price/Cash Flow 12.6x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-REFERENCE LABS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.